US Patent Trial and Appeal Board upholds validity of Lialda patent

6 October 2016

Ireland-headquartered rare diseases specialist Shire (LSE: SHP) says that the US Patent & Trademark Office’s Patent Trial and Appeal Board (PTAB) has issued its decision upholding the validity of US Patent No 6,773,720, related to Shire’s Lialda (mesalamine) product.

The petition seeking to institute inter partes review (IPR) was filed with the US PTAB in April of 2015 by the Coalition for Affordable Drugs (CFAD) II Fund. The PTAB found that the patent was valid in light of the challenges put forward by the petitioner.

Shire says it is pleased with the decision and will continue to vigorously defend its patents to protect the innovation and value Shire products bring to patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK